Telix to acquire ITM Isotope for $1.65 billion, targeting radioligand therapy market
Telix Pharmaceuticals announced it will acquire ITM Isotope Technologies Munich for $1.65 billion upfront, securing a radiopharmaceutical supply network.
The acquisition brings an R&D pipeline centered on ITM-11, a radioligand therapy that competes with Novartis’ Lutathera.
The deal includes up to $700 million in regulatory milestones linked to FDA approvals of ITM-11 in various neuroendocrine tumor indications, plus potential sales‑based payments of up to $450 million.
Analysts described the transaction as "extremely bullish," highlighting the product’s differentiated clinical profile and its potential to expand Telix’s presence in the radiopharmaceutical market.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that